BruceFScharschmidtMD

Summary

• Dr. Scharschmidt was most recently Sr. Vice President and Chief Medical & Development Officer at Hyperion Therapeutics, where he oversaw the development of glycerol phenylbutyrate (GPB, RAVICTI®), approved for treatment of urea cycle disorders in the US, Europe and Canada and the successful phase 2 trial of GPB for hepatic encephalopathy. He was inventor/co-inventor on Hyperion’s intellectual property, a member of Hyperion’s road show team leading to its 2012 IPO, 2013 secondary offering and May 2015 sale to Horizon Pharma. Bruce previously held VP positions at Novartis and Chiron, where he was involved in the development of multiple vaccines and therapeutics now approved in the US and/or Europe. Prior to joining industry, Bruce was Professor of Medicine and Chief of Gastroenterology at Univ. of CA, San Francisco (UCSF), where he was an NIH-funded investigator for two decades and helped launch the UCSF liver transplant program. Bruce is currently Independent Director, co-founder and/or consultant to several biotechnology companies.
  Bruce is author of over 200 research and review articles and multiple patents as well as of several children’s books (visit brucescharschmidt.com). He served as Editor of Sleisenger & Fordtran’s Textbook of Gastroenterology, Assoc. Editor of Gastroenterology, Editor-in-Chief of the Journal of Clinical Investigation, President of the American Society for Clinical Investigation and as mentor to colleagues in academia and industry. He is Board Certified in Internal Medicine and Gastroenterology, was a member of the National Board of Directors of the American Liver Foundation from 2005-2013 and is a member of the President’s Council Executive Committee for UCSF’s J. David Gladstone Institute. Bruce served on the External Advisory Board for the Northwestern University Feinberg School of Medicine’s (NUFSM) Clinical and Translational Science Program (NUCATS)(2008-21), is Past President of NUFSM’s Medical Association Alumni Board, was named NUFS